Exelixis Stock
Exelixis, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael Morrissey
- Employees
- 1,077
- Market cap
- $15.6 B
- IPO
- 17/04/2000
Exelixis, Inc. is a specialized healthcare/biotechnology company headquartered in the USA that focuses primarily on combating cancer. The biotech firm's portfolio includes various oncology therapeutics, such as CABOMETYX and COMETRIQ (based on cabozantinib), as well as COTELLIC for the treatment of advanced melanoma.…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Exelixis stock: price history
1D
-1.0%
1W
+4.0%
1M
+9.6%
6M
+38.6%
YTD
+42.0%
1Y
+58.7%
2Y
+112.0%
5Y
+185.2%
10Y
+449.7%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~1% stronger price swings than usual
Exelixis stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
Exelixis is a biotechnology company primarily focused on the development and commercialization of oncology therapeutics. The core business is based on the distribution of therapeutics such as CABOMETYX for the treatment of renal cell carcinoma and COMETRIQ for medullary thyroid carcinoma. A substantial portion of revenues is generated through the sale of these products, with geographic focus primarily on the United States. In addition to product sales, the company generates revenues from royalties and collaborations in pharmaceutical research. The research pipeline comprises several promising drug candidates in various stages of development targeting different cancer diseases. The business model is characterized by intellectual property protection of patented therapeutics as well as strategic partnerships with other pharmaceutical companies.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Takeda Pharmaceutical Company LimitedDescriptionAsk the agents about Exelixis
Analyst assessment of Exelixis
PRICE TARGET LOW
US$49.00
CONSENSUS
US$52.33
MEDIAN
US$52.00
PRICE TARGET HIGH
US$56.00
0
STRONG BUY
16
BUY
17
HOLD
0
SELL
0
STRONG SELL
33
TOTAL · Hold
As of: 09/10/2026
Exelixis stock metrics
P/E
18.91
P/B
8.47
EV/EBITDA
14.83
RETURN ON EQUITY
11.5%
NET MARGIN
33.7%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
03/07/2026
Free float & liquidity
FREE FLOAT
85.0%
FLOAT SHARES
213,602,685
AVG. DAILY VOLUME (30D)
2,290,694
Insider transactions (SEC)
Beckerle Mary C
WYSZOMIERSKI JACK L
Eckhardt Sue Gail
WYSZOMIERSKI JACK L
Oliver Bob
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.0%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Exelixis stock
What does Exelixis do?
Exelixis, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael Morrissey, the company employs around 1,077 people.
The IPO was on 17/04/2000; the stock trades on NASDAQ under the ticker EXEL.
What do analysts say about Exelixis stock?
33 analysts rate the stock, the consensus is Hold (as of 09/10/2026).
The average price target is US$52.33, ranging from US$49.00 to US$56.00, with a median of US$52.00.
This is an external assessment, not a statement by Market Jury.
When does Exelixis report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Exelixis pay a dividend?
No, Exelixis currently does not pay a dividend.
Which stocks are comparable to Exelixis?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Neurocrine Biosciences, Summit Therapeutics and Halozyme Therapeutics.
How can I get Exelixis stock analyzed?
Clicking "Analyze stock" lets five strategies assess Exelixis against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.